Metronomics Global Health Initiative

Home page > Publications > Papers of Interest > Metronomic in adult > The anti-angiogenic basis of metronomic

The anti-angiogenic basis of metronomic chemotherapy

Nature Reviews Cancer 4, 423-436 (June 2004) | doi:10.1038/nrc1369

R Kerbel, B. Kamen The anti-angiogenic basis of metronomic chemotherapy

Abstract In addition to proliferating cancer cells and various types of normal cells, such as those of the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the growing tumour vasculature. The anti-angiogenic efficacy of chemotherapy seems to be optimized by administering comparatively low doses of drug on a frequent or continuous schedule, with no extended interruptions — sometimes referred to as ’metronomic’ chemotherapy. In addition to reduced acute toxicity, the efficacy of metronomic chemotherapy seems to increase when administered in combination with specific anti-angiogenic drugs. Gaining better insight into the mechanisms of these effects could lessen or even eliminate the empiricism used to determine the optimal dose and schedule for metronomic chemotherapy regimens.